Profile data is unavailable for this security.
About the company
Jiangsu Aidea Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of human-source protein products. The Company is also engaged in the development and sales of some generic drugs, human immunodeficiency virus (HIV) diagnostic equipment and reagents. The Company is also engaged in the research and development of innovative drugs in anti-Acquired Immune Deficiency Syndrome (AIDS), anti-inflammatory and anti-tumor drugs fields. The Company's human-source protein products mainly include crude ulinastatin, crude urekline, crude urokinase and intermediates of ulinastatin. The Company mainly distributes its products within domestic market.
- Revenue in CNY (TTM)391.64m
- Net income in CNY-90.16m
- Incorporated2009
- Employees476.00
- LocationJiangsu Aidea Pharmaceutical Co LtdNo. 69Xinganquan West Road, Hanjiang DistrictYANGZHOU 225008ChinaCHN
- Phone+86 51 482090238
- Fax+86 51 487736366
- Websitehttps://www.aidea.com.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Orient Gene Biotech Co Ltd | 627.03m | -414.61m | 5.91bn | 2.23k | -- | 0.803 | -- | 9.43 | -2.05 | -2.05 | 3.11 | 36.51 | 0.065 | 0.9281 | 2.10 | 281,055.40 | -4.58 | 29.62 | -5.53 | 38.29 | 43.94 | 59.69 | -70.46 | 35.82 | 4.27 | -- | 0.0767 | 19.24 | -90.65 | 23.46 | -119.23 | -- | 121.04 | -- |
| Sichuan Huiyu Pharmaceutical Co Ltd | 931.96m | 147.83m | 6.03bn | 1.36k | 40.80 | 1.58 | -- | 6.47 | 0.349 | 0.349 | 2.20 | 9.01 | 0.2032 | 0.9121 | 14.88 | 683,254.60 | 3.18 | 10.41 | 3.82 | 12.76 | 84.46 | 89.89 | 15.65 | 21.42 | 2.92 | -- | 0.1299 | 20.54 | -37.92 | 76.37 | -43.86 | -- | 66.72 | -- |
| Guizhou Sanli Pharmaceutical Co Ltd | 1.71bn | 293.82m | 6.21bn | 2.28k | 21.68 | 3.98 | -- | 3.64 | 0.6988 | 0.6988 | 4.11 | 3.80 | 0.7064 | 2.58 | 3.81 | 748,477.00 | 12.34 | 12.39 | 18.37 | 16.72 | 71.52 | 70.45 | 17.47 | 16.31 | 1.67 | -- | 0.2368 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
| Jiangsu Aidea Pharmaceutical Co Ltd | 391.64m | -90.16m | 6.36bn | 476.00 | -- | 5.71 | -- | 16.23 | -0.2106 | -0.2106 | 0.9303 | 2.65 | 0.227 | 1.23 | 1.98 | 822,765.80 | -5.23 | -2.40 | -7.18 | -2.85 | 44.46 | 39.00 | -23.02 | -10.15 | 1.20 | -- | 0.2992 | -- | 68.44 | 8.24 | 38.75 | -- | -4.47 | -- |
| Zhejiang Ausun Pharmaceutical Co Ltd | 855.13m | 272.71m | 6.61bn | 1.17k | 24.22 | 2.92 | -- | 7.73 | 0.4604 | 0.4604 | 1.44 | 3.82 | 0.2876 | 1.21 | 3.71 | 728,389.90 | 9.17 | 9.38 | 12.29 | 12.84 | 54.14 | 53.09 | 31.89 | 27.14 | 1.96 | -- | 0.1592 | 23.53 | 6.83 | 27.35 | 7.87 | 42.07 | 24.32 | 50.50 |
| Shouyao Holdings Co Ltd | 5.23m | -191.79m | 6.63bn | 185.00 | -- | 6.85 | -- | 1,268.44 | -1.29 | -1.29 | 0.0352 | 6.51 | 0.0045 | 0.2644 | 5.25 | 28,265.68 | -16.55 | -37.24 | -18.01 | -42.63 | 96.50 | 96.03 | -3,667.74 | -2,251.77 | 8.49 | -- | 0.0018 | -- | 186.18 | -23.51 | -6.76 | -- | 34.59 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 1.15bn | 240.60m | 6.73bn | 1.40k | 27.86 | 2.54 | -- | 5.83 | 2.01 | 2.01 | 9.65 | 22.07 | 0.3566 | 1.54 | 7.73 | 824,469.80 | 7.43 | 8.72 | 9.15 | 10.64 | 77.92 | 85.10 | 20.84 | 19.16 | 2.59 | -- | 0.0861 | 26.80 | -4.56 | 7.76 | -8.09 | 10.91 | 17.99 | -- |
Data as of May 31 2024. Currency figures normalised to Jiangsu Aidea Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
25.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Geng Fund Management Co. , Ltd.as of 31 Dec 2023 | 32.42m | 15.03% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 9.58m | 4.44% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 7.52m | 3.49% |
| Huisheng Fund Management Co., Ltd.as of 31 Dec 2023 | 1.26m | 0.58% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 1.20m | 0.56% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 722.96k | 0.34% |
| AXA-SPDB Investment Managers Co., Ltd.as of 31 Dec 2023 | 534.80k | 0.25% |
| ABC-CA Fund Management Co., Ltd.as of 31 Dec 2023 | 438.37k | 0.20% |
| Harfor Fund Management Co., Ltd.as of 30 Jun 2023 | 420.00k | 0.20% |
| Caitong Securities Asset Management Co., Ltd.as of 31 Dec 2023 | 402.00k | 0.19% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
